Second Line Sorafenib After Pazopanib in Patients With RCC

Summary

* Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI). * Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for metastatic Renal Cell Carcinoma (mRCC). * With this trial we evaluate the efficacy of sorafenib as second line of treatment in patients treated with pazopanib for mRCC.

Timeline

Start

2016-09

Primary completion

2017-11-08

Completion

2017-11-08

Outcome

Outcome not reported

Stopped: “availability of new and more promising therapeutic agents than expected in the experimentation in question”

Publications

• Iacovelli R, Verzoni E, Grassi P, Farcomeni A, de Braud F, Procopio G. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. Tumori. 2014 Nov-Dec;100(6):e282-5. doi: 10.1700/1778.19296.

Drugs

Indications